ARRIVENT BIOPHARMA, INC. Payments of Stock Issuance Costs
ARRIVENT BIOPHARMA, INC. (AVBP) reported Payments of Stock Issuance Costs of $70.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $17.00K.
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was -$300.00K.
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-06-30 was $303.00K.
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for the quarter ending 2025-03-31 was $50.00K.
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for fiscal 2025 was $70.00K.
- ARRIVENT BIOPHARMA, INC. payments of stock issuance costs for fiscal 2023 was $2.41M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$283.00K derived: sum of 2 quarters · filed 2026-03-05 | $20.00K derived: sum of 3 quarters · filed 2026-08-12 | $70.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.00K derived: sum of 2 quarters · filed 2026-08-12 | $53.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $353.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $50.00K 10-Q · filed 2026-05-11 | |||
| 2023-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.41M 10-K · filed 2025-03-03 | ||
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |